Singapore markets closed

GILD Jan 2024 75.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
14.25+2.31 (+19.35%)
As of 01:45PM EST. Market open.
Full screen
Previous close11.94
Open15.05
Bid14.40
Ask14.75
Strike75.00
Expiry date2024-01-19
Day's range14.25 - 15.05
Contract rangeN/A
Volume8
Open interest1.99k
  • Zacks

    Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

    Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.

  • Business Wire

    U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

    FOSTER CITY, Calif., February 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in

  • Motley Fool

    Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?

    Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum. CEO Dan O'Day stated in the press release announcing the numbers, "2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015." Is Gilead Sciences stock a buy after its strongest results in seven years?